| Characteristic . | Patients, n (%) . |
|---|---|
| Patients enrolled | 21 |
| Age, median (range), years | 66 (44–83) |
| Sex | |
| Female | 13 (62) |
| Male | 8 (38) |
| Race | |
| White | 20 (95) |
| Black | 1 (5) |
| Eastern Cooperative Oncology Group PS | |
| PS 0 | 6 (29) |
| PS 1 | 15 (71) |
| Histology | |
| Adenosquamous | 1 (5) |
| Mucinous adenocarcinoma | 2 (9) |
| Adenocarcinoma | 18 (86) |
| Disease stage | |
| III | 1 (5%) |
| IV | 20 (95%) |
| Baseline CA19‐9, median (range) | 335 (4–194,446) |
| Prior surgery | 7 (33) |
| Prior chemotherapy | 14 (67) |
| FOLFIRINOX | 12 (57) |
| FOLFIRI | 1 (5) |
| Gemcitabine | 2 (9) |
| 5‐FU with radiation | 3 (14) |
| Prior lines of therapy | |
| One line | 11 (52) |
| Two lines | 3 (14) |
| Prior radiation | 4 (19) |
| Characteristic . | Patients, n (%) . |
|---|---|
| Patients enrolled | 21 |
| Age, median (range), years | 66 (44–83) |
| Sex | |
| Female | 13 (62) |
| Male | 8 (38) |
| Race | |
| White | 20 (95) |
| Black | 1 (5) |
| Eastern Cooperative Oncology Group PS | |
| PS 0 | 6 (29) |
| PS 1 | 15 (71) |
| Histology | |
| Adenosquamous | 1 (5) |
| Mucinous adenocarcinoma | 2 (9) |
| Adenocarcinoma | 18 (86) |
| Disease stage | |
| III | 1 (5%) |
| IV | 20 (95%) |
| Baseline CA19‐9, median (range) | 335 (4–194,446) |
| Prior surgery | 7 (33) |
| Prior chemotherapy | 14 (67) |
| FOLFIRINOX | 12 (57) |
| FOLFIRI | 1 (5) |
| Gemcitabine | 2 (9) |
| 5‐FU with radiation | 3 (14) |
| Prior lines of therapy | |
| One line | 11 (52) |
| Two lines | 3 (14) |
| Prior radiation | 4 (19) |
Abbreviations: 5‐FU, 5‐fluorouracil; CA19‐9, carbohydrate antigen 19‐9; PS, performance status.
| Characteristic . | Patients, n (%) . |
|---|---|
| Patients enrolled | 21 |
| Age, median (range), years | 66 (44–83) |
| Sex | |
| Female | 13 (62) |
| Male | 8 (38) |
| Race | |
| White | 20 (95) |
| Black | 1 (5) |
| Eastern Cooperative Oncology Group PS | |
| PS 0 | 6 (29) |
| PS 1 | 15 (71) |
| Histology | |
| Adenosquamous | 1 (5) |
| Mucinous adenocarcinoma | 2 (9) |
| Adenocarcinoma | 18 (86) |
| Disease stage | |
| III | 1 (5%) |
| IV | 20 (95%) |
| Baseline CA19‐9, median (range) | 335 (4–194,446) |
| Prior surgery | 7 (33) |
| Prior chemotherapy | 14 (67) |
| FOLFIRINOX | 12 (57) |
| FOLFIRI | 1 (5) |
| Gemcitabine | 2 (9) |
| 5‐FU with radiation | 3 (14) |
| Prior lines of therapy | |
| One line | 11 (52) |
| Two lines | 3 (14) |
| Prior radiation | 4 (19) |
| Characteristic . | Patients, n (%) . |
|---|---|
| Patients enrolled | 21 |
| Age, median (range), years | 66 (44–83) |
| Sex | |
| Female | 13 (62) |
| Male | 8 (38) |
| Race | |
| White | 20 (95) |
| Black | 1 (5) |
| Eastern Cooperative Oncology Group PS | |
| PS 0 | 6 (29) |
| PS 1 | 15 (71) |
| Histology | |
| Adenosquamous | 1 (5) |
| Mucinous adenocarcinoma | 2 (9) |
| Adenocarcinoma | 18 (86) |
| Disease stage | |
| III | 1 (5%) |
| IV | 20 (95%) |
| Baseline CA19‐9, median (range) | 335 (4–194,446) |
| Prior surgery | 7 (33) |
| Prior chemotherapy | 14 (67) |
| FOLFIRINOX | 12 (57) |
| FOLFIRI | 1 (5) |
| Gemcitabine | 2 (9) |
| 5‐FU with radiation | 3 (14) |
| Prior lines of therapy | |
| One line | 11 (52) |
| Two lines | 3 (14) |
| Prior radiation | 4 (19) |
Abbreviations: 5‐FU, 5‐fluorouracil; CA19‐9, carbohydrate antigen 19‐9; PS, performance status.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
